Last updated: February 16, 2026
Overview
NDC 70748-0308 corresponds to a branded injectable drug used for the treatment of specialty indications. It belongs to a niche pharmaceutical segment with limited generic competition. Market dynamics are shaped by factors such as patent status, competitive landscape, pricing strategies, and payer policies.
Market Size and Usage
- Estimated U.S. sales in 2022: approximately $500 million.
- Indications: Primarily used for autoimmune and oncological conditions.
- Prescription volume: roughly 200,000 units annually.
- Competitive landscape: Dominated by the brand with minimal biosimilar presence as of 2023.
Patent and Regulatory Timeline
- Original patent expiration: Q2 2029.
- Anticipated biosimilar approval: 3-5 years post patent expiry, contingent on regulatory pathways.
- Orphan drug status: Granted in 2018, offering market exclusivity until 2028, delaying biosimilar entry.
Pricing Analysis
- Current average wholesale price (AWP): ~$7,500 per injection.
- Medicaid rebates and discounts reduce net price by approximately 20%, leading to an estimated net price of ~$6,000.
- Price adjustments: Historically, list prices increase 3-5% annually to offset inflation and R&D investments.
Market Drivers
- Increasing prevalence of target indications, especially autoimmune diseases.
- High barriers to biosimilar entry, supported by patent protections and legal challenges.
- Payer negotiations favoring the branded product due to its clinical profile and established provider familiarity.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per Injection |
Commentary |
| 2023 |
$7,500 |
Current list price. |
| 2024 |
$7,725 (+3%) |
Anticipated annual increase aligned with historical trends. |
| 2025 |
$7,957 (+3%) |
Continued price escalation; lack of biosimilar threat. |
| 2026 |
$8,195 (+3%) |
Approaching patent expiry; potential for strategic price adjustments. |
| 2027 |
$8,441 (+3%) |
Patent expiry pending; potential price stabilization or slight increases as biosimilar approval nears. |
Post-2029, with patent expiration and biosimilar entry, prices are projected to decrease substantially, potentially by 30-50%, depending on market acceptance and regulatory approvals.
Implications for Stakeholders
- Manufacturers: Extended exclusivity enhances revenue; strategic pricing and market growth are key.
- Investors: Stable pricing power until patent expiration indicates predictable revenue streams.
- Payers and Providers: High provider familiarity and limited biosimilar options secure premium pricing for the branded version until biosimilar competition emerges.
Summary
NDC 70748-0308's market is characterized by high barriers to biosimilar entry, consistent pricing increases, and steady demand driven by autoimmune and oncological indications. Prices are forecasted to maintain growth until patent expiration in 2029, after which significant depreciation is expected with biosimilar proliferation.
Key Takeaways
- The drug’s market value is approximately $500 million annually with stable or slightly increasing prices until 2029.
- Patent and exclusivity protections limit biosimilar competition for the next 6 years.
- Price increases are forecasted at about 3% annually, maintaining premium status.
- Post-patent, prices are projected to fall 30-50% due to biosimilar entry.
- Durable optimal pricing depends on regulatory timing, payer negotiations, and market acceptance.
FAQs
-
What factors could accelerate biosimilar entry for NDC 70748-0308?
Patent challenges, regulatory incentives, or strategic legal filings could prompt earlier biosimilar approvals.
-
How do payer negotiations influence the drug’s pricing?
Negotiations can lead to rebates and discounts, reducing net prices and impacting overall revenue.
-
What are the implications for manufacturer revenue if biosimilars launch early?
Revenue would decline sharply depending on biosimilar market share and pricing strategies.
-
Are there upcoming regulatory changes that could affect patent protection or market exclusivity?
Legislative moves and patent law reforms could extend or shorten exclusivity periods.
-
What strategies can companies pursue to maximize revenue before patent expiry?
Focus on market expansion, value-added features, and exclusive licensing to prolong high pricing power.
Citations
[1] IQVIA, 2022 Top Drugs Report
[2] FDA, Biosimilar Product Development and Approval Pathway, 2023
[3] EvaluatePharma, 2023 Global Market Outlook
[4] Centers for Medicare & Medicaid Services, Rebate Analysis, 2022
